National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 53276-53277 [2018-22901]
Download as PDF
<![CDATA[
53276
Federal Register / Vol. 83, No. 204 / Monday, October 22, 2018 / Notices
part 606 have been approved under
OMB control number 0910–116.
Dated: October 16, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–22959 Filed 10–19–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
daltland on DSKBBV9HB2PROD with NOTICES
National Committee on Vital and Health
Statistics: Hearing
Pursuant to the Federal Advisory
Committee Act, the Department of
Health and Human Services (HHS)
announces the following advisory
committee hearing.
Name: National Committee on Vital
and Health Statistics (NCVHS),
Subcommittee on Standards.
Date and Times: Wednesday,
December 12, 2018: 9 a.m.–5 p.m. (EST);
Thursday, December 13, 2018: 9 a.m.–1
p.m. (EST).
Place: Omni Shoreham Hotel, 2500
Calvert Street NW, Washington, DC
20008.
Status: Open. There will be a public
comment period during the final 15
minutes of both days of the meeting.
Purpose: Health Insurance Portability
and Accountability Act (HIPAA)
legislation from 1996, as amended,1
directed the Secretary of Health and
Human Services (HHS) to publish
regulations adopting standards, code
sets and identifiers to support the
exchange of electronic health
information between covered entities.
The standards are for retail pharmacy
and medical transactions.
In its capacity to advise the HHS
Secretary on health data, statistics,
privacy, national health information
policy, and HIPAA, NCVHS is in the
final stages of the development of a
standards update and adoption
roadmap, referred to as the
Predictability Roadmap. The
development of the Predictability
Roadmap has been a year and a half
long process, achieved in collaboration
with industry stakeholders and the
standards development organizations
(SDOs). The overall vision for the
Predictability Roadmap is that:
• HIPAA covered entities and their
business associates use the adopted
standards and operating rules in a
consistent way to exchange health
information and conduct business; and
• Standards are reliably updated and
adopted so that covered entities know
1 Along with Section 1104(c) of the Patient
Protection and Affordable Care Act (ACA) of 2010.
VerDate Sep<11>2014
18:12 Oct 19, 2018
Jkt 247001
when they will need to, and/or be able
to update systems and business
processes.
To accomplish this goal, NCVHS
conducted several information gathering
activities and stakeholder engagement
meetings and workshops: In June 2017
the Subcommittee on Standards met
with each of the standards development
organizations (SDOs) to learn about
their individual maintenance processes;
in August 2017 the Subcommittee held
a visioning exercise with the SDOs and
Designated Standards Maintenance
Organization (DSMO); and in May 2018,
the Subcommittee conducted a CIO
Forum with 21 health care technology
experts and senior corporate officers
representing a cross-section of
organizations that were end-users of the
HIPAA and ACA administrative
standards. The goal of this Forum was
to elicit input for improving the
standards development, update and
adoption process, and address barriers
to use of those standards. Based on this
work, the Subcommittee on Standards
developed a draft Predictability
Roadmap comprised of 23
recommendations organized under three
major focus areas. The draft
recommendations were presented at the
September 13–14 NCVHS meeting and
are posted on the website at: https://
ncvhs.hhs.gov/wp-content/uploads/
2018/09/Presentation-NCVHS-DraftPredictability-Roadmap-RecsCoussoule-and-Goss.pdf.
The purpose of this Subcommittee
hearing is to obtain input from
stakeholders on the draft
recommendations designed to improve
the processes for updating, adopting and
using standards and operating rules, and
developing a formal Predictability
Roadmap. The Subcommittee will use
the feedback received at this hearing to
finalize recommendations to the
Secretary of HHS.
Individuals and representatives of
organizations interested in submitting
written testimony are invited to respond
to the following questions:
In general,
1. Would these recommendations as a
whole improve the predictability of the
adoption of administrative standards
and operating rules?
2. What additional recommendations
are critical to achieve predictability?
And specifically,
3. What is the value proposition of
each recommendation and what
improvements to the current state do
you believe will arise from each
recommendation/group of similar
recommendations?
4. Are there potential unintended
consequences? What are those and how
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
can they be mitigated with
modifications to the recommendations?
The questions outlined above can be
used to guide written submissions to the
Subcommittee. Written submissions
should be sent electronically to
NCVHSmail@cdc.gov with
‘‘Predictability Roadmap’’ in the subject
line no later than November 20, 2018.
The times and topics for this meeting
are subject to change. Please refer to the
posted agenda at www.ncvhs.hhs.gov for
any updates.
Contact Persons for More Information:
Substantive program information may
be obtained from Rebecca Hines, MHS,
Executive Secretary, NCVHS, National
Center for Health Statistics, Centers for
Disease Control and Prevention, 3311
Toledo Road, Hyattsville, Maryland
20782, telephone (301) 458–4715.
Information pertaining to meeting
content may be obtained from Lorraine
Doo, MSW, MPH, (410) 786–6597; and/
or Geanelle G. Herring, MSW, (410)
786–4466; Centers for Medicare &
Medicaid Services, Office of Information
Technology, Division of National
Standards, 7500 Security Boulevard,
Baltimore, Maryland, 21244. Summaries
of meetings and a roster of Committee
members are available on the NCVHS
website: www.ncvhs.hhs.gov where
further information including an agenda
and instructions to access the live audio
broadcast of the meeting will be posted.
Should you require reasonable
accommodation, please contact the CDC
Office of Equal Employment
Opportunity on (770) 488–3210 as soon
as possible.
Sharon Arnold,
Associate Deputy Assistant Secretary for
Planning and Evaluation, Science and Data
Policy, Office of the Assistant Secretary for
Planning and Evaluation.
[FR Doc. 2018–22952 Filed 10–19–18; 8:45 am]
BILLING CODE 4151–05–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\22OCN1.SGM
22OCN1
Federal Register / Vol. 83, No. 204 / Monday, October 22, 2018 / Notices
daltland on DSKBBV9HB2PROD with NOTICES
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Review of NHLBI Cardiac Surgery Network
Clinical Centers.
Date: November 14, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton BWI (Baltimore), 1100 Old
Elkridge Landing Road, Baltimore, MD
21090.
Contact Person: Shelley S. Sehnert, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7206, Bethesda, MD 20892–7924, 301–435–
0303, ssehnert@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Clinical Ancillary Studies (R01).
Date: November 16, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: YingYing Li-Smerin, MD,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, 6701 Rockledge
Drive, Room 7184, Bethesda, MD 20892–
7924, 301–827–7942, lismerin@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Early Phase Clinical Trials (R61/R33).
Date: November 16, 2018.
Time: 1:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D.
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Room 7180, Bethesda,
MD 20892–7924, 301–827–7913, creazzotl@
mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Early Phase Clinical Trials (R33).
Date: November 16, 2018.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Room 7180, Bethesda,
MD 20892–7924, 301–827–7913, creazzotl@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
VerDate Sep<11>2014
18:12 Oct 19, 2018
Jkt 247001
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 16, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–22901 Filed 10–19–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary
and Integrative Health; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended notice is hereby given of a
meeting of the Special Emphasis Panel.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel, Early Phase Clinical
Trials of Natural Products (NP).
Date: November 29, 2018.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Martina Schmidt, Ph.D.,
Chief, Office of Scientific Review, National
Center for Complementary and Integrative
Health, NIH, 6707 Democracy Blvd., Suite
401, Bethesda, MD 20892, 301–594–3456,
schmidma@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Integrative Health,
National Institutes of Health, HHS)
Dated: October 16, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–22902 Filed 10–19–18; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
53277
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Physiology and Pathobiology of
Cardiovascular and Respiratory Systems.
Date: November 6–7, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Richard D. Schneiderman,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4138,
Bethesda, MD 20817, 301–402–3995,
richard.schneiderman@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Biological Chemistry, Biophysics
and Assay Development.
Date: November 8–9, 2018.
Time: 8:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: JW Marriott New Orleans, 614 Canal
Street, New Orleans, LA 70130.
Contact Person: Vonda K. Smith, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6188,
MSC 7892, Bethesda, MD 20892, 301–435–
1789, smithvo@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Developmental Brian Disorders and
Alzheimer’s Disease Applications.
Date: November 8, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Seetha Bhagavan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5194,
E:\FR\FM\22OCN1.SGM
22OCN1
]]>Agencies
[Federal Register Volume 83, Number 204 (Monday, October 22, 2018)]
[Notices]
[Pages 53276-53277]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22901]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial
[[Page 53277]]
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Review of NHLBI Cardiac Surgery Network
Clinical Centers.
Date: November 14, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Sheraton BWI (Baltimore), 1100 Old Elkridge Landing Road,
Baltimore, MD 21090.
Contact Person: Shelley S. Sehnert, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD
20892-7924, 301-435-0303, [email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Clinical Ancillary Studies (R01).
Date: November 16, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The William F. Bolger Center, 9600 Newbridge Drive,
Potomac, MD 20854.
Contact Person: YingYing Li-Smerin, MD, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7184, Bethesda, MD
20892-7924, 301-827-7942, [email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Early Phase Clinical Trials (R61/R33).
Date: November 16, 2018.
Time: 1:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7180, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D. Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6701 Rockledge
Drive, Room 7180, Bethesda, MD 20892-7924, 301-827-7913,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Early Phase Clinical Trials (R33).
Date: November 16, 2018.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7180, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6701 Rockledge
Drive, Room 7180, Bethesda, MD 20892-7924, 301-827-7913,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: October 16, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-22901 Filed 10-19-18; 8:45 am]
BILLING CODE 4140-01-P
